Hyperthermic magnetic nanoparticle ablation of liver and pancreatic tumors

Hyperthermic magnetic nanoparticle ablation of liver and pancreatic tumors

Nanoablation

Autoritate contractantă: Unitatea Executiva pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii (UEFISCDI)


Hepatocellular carcinoma (HCC) and pancreatic adenocarcinoma (PAC) are some of the most aggressive solid malignancies, on the 3rd and 4th place in terms of mortality worldwide. Current chemotherapy and anti-angiogenic therapy options are usually inefficient, while several invasive methods have been proposed for ablation of malignant liver and pancreatic tumors. The NANO-ABLATION project has a strong innovative content, which includes: 1) a nano-ablation tester used for testing of fluids containing magnetic nanoparticles (MNPs), dosed in controlled quantities and placed in the poles of a properly calibrated RF magnetic coil, with the temperature monitored with an infrared pyrometer; 2) synthesis and analysis of different MNPs (including magnetite -NH2 or -COOH conjugates, novel magnetic materials with high Fe average magnetic moment like Fe16N2 and / or targeted MNps loaded with anti-angiogenic drugs (sorafenib or bevacizumab); 3) passive difussion of the MNPs will be tested through injection into murine models tumor xenografts, normal pig liver and pancreas, as well as human tissue explants from HCC and PAC patients, with subsequent pathology assessment of apoptosis / necrosis; 4) design of a computer controlled RFA needle, based on previous patents of one of the consortium members, might enhance RFA and nano- ablation through an optimized thermal effect over tumour and a lower impact on the surrounding healthy tissues. In conclusion, the NANO-ABLATION project brings together a critical mass of experts in biotechnology research, clinical and interventional imaging (both ultrasound and endoscopic ultrasound), nanoscale chemistry, physics and nano-toxicology to create a minimally invasive, image-guided system that will provide more accurate ablation of both hypovascular and hypervascular, liver and pancreatic tumors, through a combination of computer controlled RFA and MNPs hyperthermia, with the final aim of enhancing current insufficient ablation procedures.
...
  • Contact
  • Adrian Săftoiu
  • adriansaftoiu@aim.com
  • Fonduri
  • An : 2012
  • Data de la care : 02.07.2012
  • Data până la care : 30.06.2015
  • Sumă : 1500000  RON
Actualizat la 29.03.2023, 09:29